Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Biotech M&A: will the 2018 surge last?
  2. New fund will address misuse of drugs in UK care homes
  3. Takeda makes fourth offer of £44.3bn for Shire takeover

Company A-Z

Latest Content

T-cell biomarkers show promise for CAR-T therapy in CLL, but is it enough?

University of Pennsylvania researchers’ recent announcement of the identification of T cell biomarkers that could predict with 100% accuracy those chronic lymphocytic leukemia (CLL) patients who would experience a complete clinical response to chimeric antigen receptor (CAR)-T cell therapy is an exciting advancement.

Biotech M&A: will the 2018 surge last?

Analysts are predicting a surge of M&A activity in the biotech space, with large pharma firms looking to pad their pipelines with new acquisitions, US tax reform freeing up cash flow, and rapidly-consolidating US healthcare buyers likely to put more pressure on the price of existing drugs. How is the biotech M&A landscape likely to develop over the course of 2018?

CPHI experts: 90% of current pipeline APIs are poorly soluble

Advances in solubility and surface area are being driven by a massive change in the solubility of pipeline APIs, claimed industry experts at the Solubility Enhancement and Improving Oral Bioavailability panel of the Convention on Pharmaceutical Ingredients (CPHI) North America conference in Philadelphia, Pennyslvania, US, on Tuesday, April 24,. These experts estimated that 90% of the current drug pipeline is poorly soluble.

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top